From castration-induced apoptosis of prostatic epithelium to the use of apoptotic genes in the treatment of prostate cancer

Annals of the New York Academy of Sciences

Volumn 963, Issue , 2002, Pages 191-203

  Zhang, Y ^a   Nan, Bicheng ^a   Yu, Jiang ^a   Snabboon, Tithi ^a   Andriani, Francesca ^a   Marcelli, Marco ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Castration; Epithelium; Genes; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CASPASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; REAGENT;

APOPTOSIS; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CASTRATION; CONFERENCE PAPER; DNA MICROARRAY; GENE CONTROL; GENE OVEREXPRESSION; GENETIC MANIPULATION; HUMAN; MITOCHONDRION; NONHUMAN; PROSTATE CANCER; PROSTATE EPITHELIUM; VIRAL GENE DELIVERY SYSTEM;

EID: 0036289530     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04110.x     Document Type: Conference Paper

References (83)

1. The effect of castration, of estrogens and androgen injection on serum phosphatase in metastatic carcinoma of the prostate
2. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor
3. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases
4. Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding
5. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation
6. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity
7. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation
8. The biology of hormone refractory prostate cancer. Why does it develop?
9. Complete androgen blockade for prostate cancer: What went wrong?
10. Early androgen deprivation for prostate cancer?
11. Cancer statistics 2000
12. Caspases find a new place to hide [news]
13. Death receptors: Signaling and modulation
14. Mitochondria and apoptosis
15. Caspases: Enemies within
16. An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis
17. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-xl
18. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor
19. Regulation of cell death protease caspase-9 by phosphorylation
20. Akt phosphorylates and regulates the orphan nuclear receptor Nur77
21. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis
22. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
23. Regulated targeting of BAX to mitochondria
24. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis
25. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane
26. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis
27. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death
28. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c
29. Molecular characterization of mitochondrial apoptosis-inducing factor
30. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition
31. Endonuclease G is an apoptotic DNase when released from mitochondria
32. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
33. Androgen-induced proliferative quiescence in prostate cancer cells: The role of AS3 as its mediator
34. Regulation of proliferation and production of prostate specific antigen in androgen-sensitive prostate cancer cells LNCaP, by dihydrotestosterone
35. Negative controls of cell proliferation: Human prostate cancers and androgens
36. Activation of programmed cell death in the rat ventral prostate after castration
37. Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation
38. Cellular response to androgen depletion and repletion in the rat ventral prostate: Autoradiography and morphometric analysis
39. Hormonal control of apoptosis: The rat prostate gland as a model system
40. Characterization and cloning of androgen-repressed mRNAs from rat ventral prostate
41. Expression of transforming growth factor-b in the rat ventral prostate during castration-induced programmed cell death
42. Cascade induction of c-fos, c-myc, and heat shock 70K transcripts during regression of the ventral prostate gland
43. Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract
44. Isolation and characterization of transcripts induced by androgen withdrawal and apoptotic cell death in the rat ventral prostate
45. Identification of glutathione S-transferase Yb1 mRNA as the androgen-repressed mRNA by cDNA cloning and sequence analysis
46. Antisense TR3 orphan receptor can increase prostate cancer cell viability with etoposide treatment
47. Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin)
48. Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostates
49. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
50. Detection of the apoptosis suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers
51. L underlies the molecular basis for resistance to staurosporine-induced apoptosis on PC-3 cells
52. Genes regulated by androgen in the rat ventral prostate
53. Calreticulin expression is associated with androgen regulation of the sensitivity to calcium ionophore-induced apoptosis in LNCaP prostate cancer cells
54. Programmed death of nonproliferating androgen-independent prostatic cancer cells
55. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin
56. Characterization of calcium release-activated apoptosis of LNCaP prostate cancer cells
57. Rapid reduction in blood flow to the rat ventral prostate gland after castration: Preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival
58. Regulation of apoptosis in the prostate gland by androgenic steroids
59. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland
60. Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells
61. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B
62. Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells
63. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway
64. Androgen blocks apoptosis of hormone-dependent prostate cancer cells
65. Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression
66. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1
67. Delineation of prognostic biomarkers in prostate cancer
68. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP
69. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for the treatment of prostate cancer
70. Heterogeneous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to staurosporine-induced apoptosis, expression of Bcl-2 family members, and caspase activation
71. Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C elegans cell death gene ced-3
72. ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B
73. Generation of constitutively active recombinant caspases-3 and -6 by rearrangment of their subunit
74. Induction of apoptosis in BPH stromal cells by adenoviral-mediated overexpression of caspase-7
75. Adenoviral-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer
76. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax
77. Bax-induced cell death may not require interleukin 1beta-converting enzyme-like proteases
78. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis
79. Antitumor effect of adenovirus-mediated Bax gene transfer on p53- sensitive and p53-resistant cancer lines
80. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo
81. Use of the probasin promoter ARR(2)PB to express bax in androgen receptor-positive prostate cancer cells
82. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
83. Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial and basic biology